Theratechnologies Inc (TSE:TH) insider Christian Marsolais purchased 3,000 shares of the stock in a transaction on Tuesday, July 18th. The stock was acquired at an average price of C$7.12 per share, for a total transaction of C$21,360.00.
Shares of Theratechnologies Inc (TSE:TH) traded down 1.65% during trading on Friday, reaching $7.16. 138,329 shares of the company’s stock were exchanged. Theratechnologies Inc has a 12 month low of $2.35 and a 12 month high of $8.72. The firm’s market cap is $532.81 million. The stock has a 50-day moving average price of $7.88 and a 200 day moving average price of $6.24.
Several equities analysts have recently commented on the stock. Scotiabank reissued an “outperform” rating and set a C$9.50 target price on shares of Theratechnologies in a report on Wednesday, June 21st. Canaccord Genuity reiterated a “speculative buy” rating and issued a C$7.50 target price on shares of Theratechnologies in a report on Friday, May 5th. Finally, National Bank Financial reiterated an “outperform” rating and issued a C$7.15 target price on shares of Theratechnologies in a report on Thursday, May 4th.
Theratechnologies Company Profile
Theratechnologies Inc is a specialty pharmaceutical company. The Company addresses medical needs to promote healthy living among human immunodeficiency virus (HIV) patients. Its products include EGRIFTA and Ibalizumab. EGRIFTA (tesamorelin for injection) refers to tesamorelin and it is indicated for the reduction of excess abdominal fat in HIV infected patients with lipodystrophy.
Receive News & Ratings for Theratechnologies Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies Inc and related companies with MarketBeat.com's FREE daily email newsletter.